Institute of Chemical Biology - National Hellenic Research Foundation

Biomarker Discovery & Translational Research
Dr. Theodora Katsila | Associate Researcher, Group Leader

About Team Collaborations Funding Publications

We translate information growth to knowledge growth

Craving for brain teasers, our strategic steps towards goal achievement are bulletproof. Translational biomarkers, being molecular and digital entities, represent a key strategy for innovation and knowledge creation.

Vision

State-of-the-art drug repurposing
Extracellular vesicles/ exosomes as pioneers for translational precision medicine
Map inter-individual variability upon xenobiotics profiling

Mission

Next-gen life sciences breakthroughs
Biomedical innovation
Disruptive healthcare solutions

Roadmap

Better-informed decision-making
Content- and data- driven analyses
Acceleration of impactful innovations

Toolbox

Multi-omics
ADME-TOX in 3D
3D cell models & cheminformatics

Within the chemical biology space, we aim to catalyse the transition from serendipity-driven to data-driven translational precision medicine. This is a paradigm shift that comes with a need for biomarker-guided trial design and patient-centric companion solutions. For this, we apply a. mass spectrometry-based multi-omics and profiling of extracellular vesicles/ exosomes, b. 3D cell models and cheminformatics, c. ADME-Tox in 3D, and d. machine learning, deep learning and computational statistics to disrupt healthcare solutions and empower biomedical innovation.

The strategy of the Lab is based on the NHRF excellence objective-2 and is informed by the consensus of FDA and EMA on translational biomarkers.

Based on their experience and expertise, the team supports fit for purpose to full compliance. The team advises on study design, analytical methodology and pull through from non-clinical to clinical use plus companion diagnostics regulatory submissions.

Current objectives

Major outcomes & achievements

State-of-the-art drug repurposing

Activity A. CloudScreen, a “one-stop-shop” next generation computational platform for drug repurposing

CloudScreen, our “one-stop-shop” next generation computational platform for drug repurposing goes beyond existing strategies, as it (a) is not limited to 1D data, but curates/ integrates/ analyzes/ interprets 1D and 3D data coming from molecular design and computational chemistry outputs; (b) minimizes confounding in data mining/ integration/ analysis and promotes unbiased decision-making via the synergy of human and machine (artificial intelligence) reasoning capabilities (i) data mining services, ii) collaboration support services, and iii) decision making services; (c) provides dynamic update capabilities and extends text data services (patents, ethics); and (d) serves as an “one-stop shop” tool for predicting and evaluating the efficacy and toxicity of repurposed biomolecules via ADME-Tox profiling in 3D. This research is supported by the European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH-CREATE-INNOVATE (project code: T2EDK-03153).

Selected Publications

Bafiti V., Ouzounis S., Siapi E., Grypari I.M., Theofanopoulos A., Panagiotopoulos V., Zolota V., Kardamakis D., Katsila T*. Metabolites, 2023, 13(3):362.
Katsila T*, Chasapi SA, Gomez Tamayo JC, Chalikiopoulou C, Siapi E, Moros G, Zoumpoulakis P, Spyroulias GA, Kardamakis D. Cancers, 2021, 13(12):2877.

Selected Outreach & Events

CLOUDSCREEN is one out of the five innovative ideas put forward within the Greek Start-up ecosystem selected by Pfizer. The start4health challenge addresses the Digital Health landscape in shaping the future of health.
We were selected to present CLOUDSCREEN: a graph-based drug repurposing platform empowered by machine learning
V. Bafiti, M.T. Matsoukas, V. Zolota, D. Kardamakis, T. Katsila* EMBO Workshop. The DNA damage response, immunity and aging, Singapore, Singapore. 2022
Chalikiopoulou C and Katsila T*. EACR 2022 Congress - Innovative Cancer Science: Translating Biology to Medicine, Seville, Spain. 2022
V. Bafiti, V. Panagiotopoulos, M.T. Matsoukas, V. Zolota, D. Kardamakis, T. Katsila*. EACR 2022 Congress - Innovative Cancer Science: Translating Biology to Medicine, Seville, Spain. 2022
Chalikiopoulou C., Katsila T*. Targeted proteomics: Experimental design and data analysis, EMBO Practical Course (web event). 2021
V. Bafiti, M.T. Matsoukas, V. Zolota, D. Kardamakis*, T. Katsila* First ESN-ISN School “From Neurodegeneration to Neural Carcinogenesis: Mechanisms and Common Biologies” [Scholarship to Ms. Bafiti], Athens, Greece. 2021
V. Bafiti, M.T. Matsoukas, V. Zolota, D. Kardamakis*, T. Katsila* 10th International Conference of the Hellenic Crystallographic Association, Athens, Greece. 2021

Activity B. Proteogenomics profiling of the 3D cell microenvironment for drug repurposing

We exploit the 3D cell microenvironment via profiling of extracellular vesicles/ exosomes as the means to define the druggable key-players as well as identify and validate candidate companion biomarkers. For this, LC-MSn and high-resolution particle-by-particle 3D fluorescent microscopy measurements are coupled. Extracellular vesicles and exosomes also serve as a toolbox for drug resistance and drug-drug interactions.

Selected Outreach & Events

Highlighted among esteemed colleagues https://www.hupo.org/Humans-of-HUPO/
Excited to discuss exosomal metabolomics in health and disease
Chalikiopoulou C., Katsila T*. Targeted proteomics: Experimental design and data analysis, EMBO Practical Course (web event). 2021

Activity C. ADME-Tox in 3D assays and services in a 3-tier strategy; in silico, in vitro, in vivo (EMA CHMP, FDA Guidance for Industy), Funded by private funders, industry.

Selected Publications

Kannavou M., Karali K., Katsila T., Siapi E., Marazioti A., Klepetsanis P., Calogeropoulou T., Charalampopoulos I., Antimisiaris S.G. Development and Comparative In Vitro and In Vivo Study of BNN27 Mucoadhesive Liposomes and Nanoemulsions for Nose-to-Brain Delivery. Pharmaceutics, 2023, 15:419.
Vachlioti E., Ferikoglou S., Georgiou X., Karampatsis V., Afratis K., Bafiti V., Savard M., Papaioannou D., Katsila T., Gobeil F. Jr, Rassias G. Arch Pharm, 2023, e2200610.
T. Rogdakis, D. Charou, A. Latorrata, E. Papadimitriou, A. Tsengenes, C. Athanasiou, M. Papadopoulou, C. Chalikiopoulou, T. Katsila, I. Ramos, K. C. Prousis, R. C. Wade, K. Sidiropoulou, T. Calogeropoulou, A. Gravanis, I. Charalampopoulos. Biomedicines, 2022, 10(3):614.
C. Yilmaz, T. Rogdakis, A. Latorrata, E. Thanou, E. Papadimitriou, E. Siapi, K.W. Li, T. Katsila, T. Calogeropoulou, I. Charalampopoulos, V.I. Alexaki. Biomolecules, 2022, 12(3):424.

Selected Outreach & Events

Participation in 86th Thessaloniki International Fair http://www.eie.gr/nhrf/news/2022/2022_09_05_NHRF_TIF.pdf and https://www.amna.gr/macedonia/article/677271/Ellinoamerikaniki-sunergasia-gia-ti-grigori-anichneusi-antisomaton-tou-neou-koronoiou
PK/ BIOPHARMACEUTICS WEBINAR, EuroNeuroTrophin Learning Scenarios (web event). 2021
https://www.euroneurotrophin.eu/results.html
Pre-validation and ADME-Tox studies of the Photostick immunosensing system. 2021
https://www.sev.org.gr/members_news/uni-pharma-sars-cov-2-protoporiako-elliniko-foteino-test-antisomaton/

Activity D. DeepInhibition

Activity Ε. DeepEVision

Map inter-individual variability upon xenobiotics profiling

Activity A. Monitoring of immunomodulatory mechanisms

We employ multi-omics (LC-MSn) and high-resolution particle-by-particle 3D fluorescent microscopy (extracellular vesicles/ exosomes; nature, number, cargos). The secretome and membrane proteome may add an extra information layer.

Selected Publications

T. Katsila, M. Juliachs, J. Gregori, T. Macarulla, L. Villarreal, A. Bardelli, C. Torrance, E. Elez, J. Tabernero, J. Villanueva. Clin Cancer Res, 2014, 20: 6346.
Gregori J, Méndez O, Katsila T, Pujals M, Salvans C, Villarreal L, Arribas J, Tabernero J, Sánchez A, Villanueva J. J Proteome Res, 2014, 13:3706.

Selected Outreach & Events

Katsila T. HPC-Europa3, 3rd User Group Meeting (web event). 2021
Descubren un marcador para monitorizar el cáncer colorrectal con muestras de sangre. EQUIPO DEL VHIO BARCELONA, 30 Oct. (EUROPA PRESS) - Investigadores del Vall d'Hebron Instituto de Oncología (VHIO) han descubierto un marcador que permitirá monitorizar el tratamiento del cáncer colorrectal a través de muestras de sangre, lo que supone un nuevo método práctico y no invasivo.
https://www.europapress.es/catalunya/noticia-descubren-marcador-monitorizar-cancer-colorrectal-muestras-sangre-20141030110736.html
La sangre revela si el tratamiento del cáncer de colon es efectivo. Viernes, 31 de octubre del 2014. Científicos del Hospital Vall d'Hebron de Barcelona han descubierto un nuevo marcador que permite comprobar si el tratamiento del cáncer colorrectal que recibe un paciente es efectivo o no mediante un simple análisis de sangre. https://www.elperiodico.com/es/sanidad/20141030/la-sangre-revela-si-el-tratamiento-del-cancer-de-colon-es-efectivo-3649003

Patent

Fundacio Privada Institut d’Investigacio Oncologica de Vall Hebron, 2014. A method for monitoring the treatment of patients with tumors expressing EGFR. EU WO2015/189106, issued December 17, 2015.

Activity B. Bioenergetics & Oncometabolism

The accumulation of cell biomass is associated with dramatically increased bioenergetic and biosynthetic demand. Metabolic reprogramming, once thought as an epiphenomenon, currently, relates to tumorigenesis and metastasis, often in response to extracellular fate-decisive signals.

Selected Publications

Bafiti V., Katsila T.* OMICS, 2022, 26(10): 542-551.
A. Poulaki, T. Katsila, S. Giannouli, J.C. Gomez Tamayo, I. Stergiou, A.G. Tzioufas, M. Voulgarelis. Leuk Res, 2021, 108 (suppl1): 106681
Poulaki A¥, Katsila T¥, Stergiou IE, Giannouli S, Gόmez-Tamayo JC, Piperaki ET, Kambas K, Dimitrakopoulou A, Patrinos GP, Tzioufas AG, Voulgarelis M. Cancers, 2020, 12(12):3520. ¥1st authorship shared

Selected Outreach & Events

V. Bafiti, V. Panagiotopoulos, M.T. Matsoukas, V. Zolota, D. Kardamakis, T. Katsila* EACR 2022 Congress - Innovative Cancer Science: Translating Biology to Medicine, Seville, Spain. 2022
V. Bafiti, M.T. Matsoukas, V. Zolota, D. Kardamakis*, T. Katsila* First ESN-ISN School “From Neurodegeneration to Neural Carcinogenesis: Mechanisms and Common Biologies” [Scholarship to Ms. Bafiti], Athens, Greece. 2021
Poulaki A, Katsila T, Giannouli S, Gomez-Tamayo JC, Stergiou IE, Tzioufas AG, Voulgarelis M. 16th International Congress on Myelodysplastic Syndromes (web event). 2021
Poulaki A, Katsila T, Stergiou IE, Giannouli S, Gomez-Tamayo JC, Kambas K, Patrinos GP, Voulgarelis M. European Hematology Association (EHA) (web event). 2020
Katsila T, Poulaki A, Stergiou IE, Giannouli S, Gomez-Tamayo JC, Kambas K, Patrinos GP, Tzioufas AG, Voulgarelis M. 16th Annual Conference, Metabolomics 2020 (web event)

Activity C. Biomarkers to the Rescue

In-house capabilities are coupled with strategic networks and partnerships for discovery, validation and clinical development of biomarkers.

Translational biomarkers (target, mechanism & disease biomarkers) identify the impact of a chemical entity on organs or tissues before a clinical effect is evident.
Diagnostic biomarkers (predictive, prognostic & resistance biomarkers) empower patient stratification and enable clinical decisions for potential combinations and/ or next-line therapies. Diagnostic biomarkers maximize therapeutic effects/ minimize ADRs.
Pharmacodynamic biomarkers used in pre- and post-treatment settings may shed light to the extent of target modulation, provide biological proof-of-activity, and inform clinical decision making (dosing amounts and/or schedules).
Companion diagnostics are intended for launch with a therapeutic drug and enable clinical decision-making (diagnostic or pharmacodynamic biomarker utility)

Selected Publications

Swen J.J., van der Wouden C.H., Manson L.E., Abdullah-Koolmees H., Blagec K., Blagus T., Böhringer S., Cambon-Thomsen A., Cecchin E., Cheung K.C., Deneer V.H., Dupui M., Ingelman-Sundberg M., Jonsson S., Joefield-Roka C., Just K.S., Karlsson M.O., Konta L., Koopmann R., Kriek M., Lehr T., Mitropoulou C., Rial-Sebbag E., Rollinson V., Roncato R., Samwald M., Schaeffeler E., Skokou M., Schwab M., Steinberger D., Stingl J.C., Tremmel R., Turner R.M., van Rhenen M.H., Dávila Fajardo C.L., Dolžan V., Patrinos G.P., Pirmohamed M., Sunder-Plassmann G., Toffoli G., Guchelaar H.J.; Ubiquitous Pharmacogenomics Consortium. Lancet, 2023, 401(10374): 347
Kumuthini J, Zick B, Balasopoulou A, Chalikiopoulou C, Dandara C, El-Kamah G, Findley L, Katsila T, Li R, Maceda EB, Monye H, Rada G, Thong MK, Wanigasekera T, Kennel H, Marimuthu V; G2MC Evidence investigators, Williams MS, Al-Mulla F, Abramowicz M. Hum Genet, 2022, 141:1697
Katsila T, Juliachs M, Gregori J, Macarulla T, Villarreal L, Bardelli A, Torrance C, Elez E, Tabernero J, Villanueva J. Clin Cancer Res, 2014, 20:6346

Selected Outreach & Events

BiomarkerDiscovery_TranslationalResearch_01

Activity D. From genotype-to-phenotype associations toward the clinical interpretome

BiomarkerDiscovery_TranslationalResearch_03 The team focus is on contextual data, data reliability and interpretation.
An artificial-human intelligence workspace facilitates data mining and curation to empower data reliability and reproducibility.

This is an illustration of an active synergistic workspace in which multi-faceted data derived from diverse and distributed sources is mined and interrogated. Interoperability is facilitated by the same synergy of human and artificial intelligence which is also anticipated to diminish biases. Nodes may represent ideas, comments, notes, services, data. Lines represent network interactions; those in light blue are those that exhibit evidence-based dominance, those in red are those that fail, while those in dark blue are the ones to be re-visited. In such a way, contextual data integration results in an evidence-based dominant outcome (node in red). Contextual or out-of- context data are equally re-visited and interrogated, and they will only survive, if evidence-based.

Selected Publications

V. Bafiti, S. Ouzounis, C. Chalikiopoulou, E. Grigorakou, I.M. Grypari, G. Gregoriou, A. Theofanopoulos, V. Panagiotopoulos, E. Prodromidi, D. Kavouras, V. Zolota, D. Kardamakis, T. Katsila*. Curr Oncol, 2022, 29(6), 4351
Jenko Bizjan B, Katsila T, Tesovnik T, Šket R, Debeljak M, Matsoukas MT, Kovač J. Comput Struct Biotechnol J, 2019, 18:83
Katsila and Matsoukas, 2018, Expert Opin Drug Discov, 13:791

Selected Outreach & Events

Group Structure and Personnel

Dr. Theodora Katsila, Associate Researcher, Research Assistant Professor
Head of the Laboratory of Biomarker Discovery & Translational Research

Post-doctoral Research Associates
Constantina Chalikiopoulou, PhD

Ph.D. candidates
Vivi Bafiti, MSc
Andreas Gkanas, MSc
Sotiris Ouzounis, MSc

MSc students
Ms. Nefeli Platania, MSc Clinical Biochemistry-Molecular Diagnostics. National & Kapodistrian University of Athens
Ms. Athina Kyriakidou, MSc Oncology: From Oncogenesis to Therapy. NHRF/ICB; University of Crete
Mr. Themistoklis Molochadis, MSc Bioentrepreneurship. NHRF/ICB; University of Thessaly
Ms. Konstantina Marina Nikolaou, MSc Clinical Biochemistry-Molecular Diagnostics, National & Kapodistrian University of Athens

Laboratory Alumni

Post-doctoral Research Associates
Dr. Angeliki Balasopoulou. State Scholarships Foundation (IKY) Post-doctoral research fellow (2020 – 2022)
Dr. Despoina Antonakaki (2020 – 2021)

MSc students
Ms. Stavroula Giannakopoulou, National&Kapodistrian University of Athens (2021-2022)
Mr. Burhan Waheed, Imperial College London (2020)
Ms. Apostolia Zarmpala, NHRF; University of Thessaly (2020-2021)
Ms. Maria Ioanna Ragkousi, NHRF; University of Crete (2020-2021)
Ms. Danae Strantzali, National & Kapodistrian University of Athens (2019-2022)
Ms. Eirini Manou, National & Kapodistrian University of Athens (2019-2021)
Mr. Antonis Tsintarakis, National & Kapodistrian University of Athens (2019-2021)

BSc students
Ms. Nefeli Platania, National & Kapodistrian University of Athens (2019-2021)

Internships
Ms. Vasiliki Miliou, ACS Athens (2022)
Mr. Gregory Gregoriou, ACS Athens (2020)
Ms. Eftychia Grigorakou, University of West Attica (2021)
Ms. Marina Constantina Grigoropoulou, University of West Attica (2021)

Collaborations

BiomarkerDiscovery_TranslationalResearch_01

Collaborations with private entities

ATHROA INNOVATIONS PC
CHROMACURE SA
CLINIGEN Ltd
CloudPharm PC
LIFE NLB Ltd
PhoreMost Ltd
Rontis Hellas SA

Funding

	2023-2027. HORIZON EUROPE - KDT Research & Innovation Actions. Project title: “Intelligent neural system for bidirectional connection with exoprostheses and exoskeletons (NerveRepack)”. Total budget: 15,575,733.75 €. Lab budget: 400,000.00 €. Role: Partner.
	2023-2024. Partnership for Advanced Computing in Europe. Project title: “DeepEVision: An end-to-end deep learning framework for the fully automated annotation, quantification, and characterization of extracellular vesicles in transmission electron microscopy images”. Role: Principal Investigator.
	2023. European High-Performance Computing Joint Undertaking. Project title: “DeepInhibition: IC50 prediction through ligand-receptor pairs interactions”. Role: Principal Investigator.
	2022-2026. COST Action CA21135. Project title: “Modelling immunotherapy response and toxicity in cancer (IMMUNO-model)”. Role: Partner.
	2022. HPC-GRNET. Project title: “Extending 3D Drug Repurposing predictions to the human Variome and extended (AlphaFold) Proteome space”. Role: Principal Investigator.
	2021. EPIC-XS Grant. EPIC-XS project 371. Project title: “An integrated model to gain mechanistic insights in glioblastoma prognosis”. Budget: 20,532.00 €. Role: Principal Investigator.
	2021-2025. ADME-Tox services. Private funding, Industry. Budget: 25,000.00 €. Role: Principal Investigator
	2021-2025. ADME-Tox services. Private funding, Industry. Budget: 22,070.90 €. Role: Principal Investigator
	2020-2023. National Strategic Reference Framework 2014-2020. General Secretariat of Research and Technology-Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH-CREATE-INNOVATE (project code: T2EDK-03153). Project title: “CLOUDSCREEN”. Total budget: 469,791.88 €. Lab budget: 352,561.98 €. Role: Principal Investigator. https://cloudscreen.gr/?lang=en
	2020-2023. National Strategic Reference Framework 2014-2020. General Secretariat of Research and Technology – Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH-CREATE-INNOVATE (project code: T2EDK-03847). Project title: “Design and development of a novel food supplement for osteoporosis based on gut microbiome mechanisms. Efficacy and tolerability assessment”. Total budget: 952,080.00 €. Lab budget: 62,760.00 €. Role: Partner. https://osteome.eu/?page_id=40
	2020-2022. State Scholarships Foundation (IKY). Operational Programme «Human Resources Development, Education and Lifelong Learning» in the context of the project “Reinforcement of Postdoctoral Researchers - 2nd Cycle” (MIS-5033021). Post-doctoral research fellow: Dr. Angeliki Balasopoulou. Total budget: 26,400.00 €. Lab budget: 26,400.00 €. Role: Coordinator.
	2020. HPC-3 Europa Transnational Access Grant. Project code: HPC17B9U3T. Role: Principal Investigator.
	2016 – 2017. Private funding, Industry. Budget: 22,000.00 £. Role: Principal Investigator (Dual PI)

Selected Publications

Chalikiopoulou C., Gómez-Tamayo J.C., Katsila T*. Untargeted Metabolomics for Disease-Specific Signatures. Methods Mol Biol, 2023, 2571:71.
Bafiti V., Ouzounis S., Siapi E., Grypari I.M., Theofanopoulos A., Panagiotopoulos V., Zolota V., Kardamakis D., Katsila T*. Bioenergetic Profiling in Glioblastoma Multiforme Patients with Different Clinical Outcomes. Metabolites, 2023, 13(3):362.
Swen J.J., van der Wouden C.H., Manson L.E., Abdullah-Koolmees H., Blagec K., Blagus T., Böhringer S., Cambon-Thomsen A., Cecchin E., Cheung K.C., Deneer V.H., Dupui M., Ingelman-Sundberg M., Jonsson S., Joefield-Roka C., Just K.S., Karlsson M.O., Konta L., Koopmann R., Kriek M., Lehr T., Mitropoulou C., Rial-Sebbag E., Rollinson V., Roncato R., Samwald M., Schaeffeler E., Skokou M., Schwab M., Steinberger D., Stingl J.C., Tremmel R., Turner R.M., van Rhenen M.H., Dávila Fajardo C.L., Dolžan V., Patrinos G.P., Pirmohamed M., Sunder-Plassmann G., Toffoli G., Guchelaar H.J.; Ubiquitous Pharmacogenomics Consortium. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet, 2023, 401(10374): 347-356.
Kannavou M., Karali K., Katsila T., Siapi E., Marazioti A., Klepetsanis P., Calogeropoulou T., Charalampopoulos I., Antimisiaris S.G. Development and Comparative In Vitro and In Vivo Study of BNN27 Mucoadhesive Liposomes and Nanoemulsions for Nose-to-Brain Delivery. Pharmaceutics, 2023, 15:419.
Vachlioti E., Ferikoglou S., Georgiou X., Karampatsis V., Afratis K., Bafiti V., Savard M., Papaioannou D., Katsila T., Gobeil F. Jr, Rassias G. Development of a multigram synthesis of the bradykinin receptor 2 agonist FR-190997 and analogs thereof. Arch Pharm, 2023, e2200610.
Bafiti V., Katsila T.* Pharmacometabolomics-Based Translational Biomarkers: How to Navigate the Data Ocean. OMICS, 2022, 26(10): 542-551.
V. Bafiti, S. Ouzounis, C. Chalikiopoulou, E. Grigorakou, I.M. Grypari, G. Gregoriou, A. Theofanopoulos, V. Panagiotopoulos, E. Prodromidi, D. Kavouras, V. Zolota, D. Kardamakis, T. Katsila*. A 3-miRNA Signature Enables Risk Stratification in Glioblastoma Multiforme Patients with Different Clinical Outcomes. Curr Oncol, 2022, 29(6), 4351-4331.
Kumuthini J, Zick B, Balasopoulou A, Chalikiopoulou C, Dandara C, El-Kamah G, Findley L, Katsila T, Li R, Maceda EB, Monye H, Rada G, Thong MK, Wanigasekera T, Kennel H, Marimuthu V; G2MC Evidence investigators, Williams MS, Al-Mulla F, Abramowicz M. The clinical utility of polygenic risk scores in genomic medicine practices: a systematic review. Hum Genet, 2022, 141(11):1697-1704.
C. Yilmaz, T. Rogdakis, A. Latorrata, E. Thanou, E. Papadimitriou, E. Siapi, K.W. Li, T. Katsila, T. Calogeropoulou, I. Charalampopoulos, V.I. Alexaki. ENT-A010, a Novel Steroid Derivative, Displays Neuroprotective Functions and Modulates Microglial Responses Biomolecules, 2022, 12(3):424.
Rogdakis T., Charou D., Latorrata A., Papadimitriou E., Tsengenes A., Athanasiou C., Papadopoulou M., Chalikiopoulou C., Katsila T., Ramos I., Prousis K.C., Wade R.C., Sidiropoulou K., Calogeropoulou T., Gravanis A., Charalampopoulos I. Development and Biological Characterization of a Novel Selective TrkA Agonist with Neuroprotective Properties against Amyloid Toxicity. Biomedicines, 2022, 10(3):614
Katsila T*, Chasapi SA, Gomez Tamayo JC, Chalikiopoulou C, Siapi E, Moros G, Zoumpoulakis P, Spyroulias GA, Kardamakis D. Three-Dimensional Cell Metabolomics Deciphers the Anti-Angiogenic Properties of the Radioprotectant Amifostine. Cancers, 2021, 13(12):2877.
Jenko Bizjan B, Katsila T, Tesovnik T, Šket R, Debeljak M, Matsoukas MT, Kovač J. Challenges in identifying large germline structural variants for clinical use by long read sequencing. Comput Struct Biotechnol J, 2020, 18:83.
Katsila T., Matsoukas M.T. How far have we come with contextual data integration in drug discovery? Expert Opin Drug Discov, 2018, 13:791.
Katsila T*., Liontos M, Patrinos GP, Bamias A, Kardamakis D. The New Age of -omics in Urothelial Cancer - Re-wording Its Diagnosis and Treatment. EBioMedicine, 2018, 28:43.
Katsila T., Juliachs M., Gregori J., Macarulla T., Villarreal L., Bardelli A., Torrance C., Elez E., Tabernero J., Villanueva J. Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer. Clin Cancer Res, 2014, 20:6346.
Gregori J., Méndez O., Katsila T., Pujals M., Salvans C., Villarreal L., Arribas J., Tabernero J., Sánchez A., Villanueva J. Enhancing the Biological Relevance of Secretome-Based Proteomics by Linking Tumor Cell Proliferation and Protein Secretion. J Proteome Res, 2014, 13(8):3706.

file_icon Full list of Publications [pdf]